KR20230112091A - Spray solution preparation for capturing influenza with onfluenza receptor factor and process for removing influenza using the same - Google Patents

Abstract

The present invention relates to a spray solution formulation for influenza capture using an influenza receptor component and a method for removing influenza using the same, and more particularly, to an influenza receptor component that specifically binds to hemagglutinin (HA) protein of influenza and a surface-immobilized solid carrier. According to the present invention, even if the virus contacts the human body, it is possible to drastically reduce the chance of infection by capturing and inactivating the virus using an influenza binding derivative and a carrier that bind to the surface of the virus.

Description

Spray solution preparation for capturing influenza using influenza receptor component and method for removing influenza using the same {Spray solution preparation for capturing influenza with onfluenza receptor factor and process for removing influenza using the same}

The present invention relates to a spray solution formulation for influenza capture using an influenza receptor component and a method for removing influenza using the same, and more particularly, to a spray solution formulation for influenza capture using a derivative compound in which an influenza receptor component that specifically binds to Hemagglutinin (HA) protein of influenza and a solid carrier immobilized on a surface are coupled to a spray solution formulation for influenza capture and a method for removing influenza using the same.

Influenza viruses infect the respiratory system, cause systemic symptoms, periodically change their appearance, and migrate to other hosts before they die without killing the host, so scientists speculate that the influenza virus will survive until the end of the human race. It is a virus that causes the greatest economic loss to mankind, and preventive vaccines and treatments are being developed one after another, but the situation is not catching up with the mutation of the virus, and fundamental virus treatment has not yet been performed.

Accordingly, with the spread of various infectious diseases, it is a time when disinfection and sanitation management are needed more than ever. As a result, as the concept of 'space defense' emerges one step further from the concept of 'contact defense' such as washing hands and wearing a mask to prevent virus infection, interest in related products is increasing. 'Space defense' refers to a method of inactivating or killing viruses in the space itself where viruses may exist in order to minimize the possibility of infection with various bacteria or viruses floating in the air in a specific space, thereby lowering the possibility of spreading the virus. In other words, it is a preventive method to minimize virus droplet infection in everyday life spaces such as houses, offices, elevators, restaurants, automobiles, hotels, child care facilities, and public places such as churches, educational centers, schools, and concert halls. In particular, according to the World Health Organization (WHO), swine flu and coronaviruses are contagious from person to person, and it is reported that most droplet infections caused by droplets spread in the air through coughing or sneezing are highly likely. Therefore, the importance of quarantine against virus particles present in the air of a space where many people work or live is increasing day by day.

Therefore, although efforts including diagnosis and treatment of viruses are rapidly advancing, measures for prevention are still urgently needed.

Korean Publication No. 10-2020-0023226 (03/04/2020) Korea Registration No. 10-1748093 (June 9, 2017)

As a result of a long-term study in order to improve the problems of the conventional techniques as described above and to minimize the risk of infection by pathogenic viruses, the inventors of the present invention, as described below, prepared a spray formulation using a derivative for influenza capture in which an influenza receptor component that specifically binds to the hemagglutinin (HA) protein of influenza and a solid carrier fixed on its surface was combined. found that the present invention was completed.

Accordingly, an object of the present invention is to provide a spray solution formulation for capturing influenza, which can dramatically reduce the chance of infection of a virus by inactivating the virus even when it contacts a human body, and a method for removing influenza using the same, by using an influenza binding derivative in which an influenza receptor component that specifically binds to influenza's Hemagglutinin (HA) protein that specifically binds to influenza and a solid carrier immobilized on its surface is coupled.

Such an object of the present invention, in one aspect,

A derivative for binding influenza and the remaining amount of additives;

The derivative for binding influenza can be achieved by a spray solution formulation for capturing influenza, characterized in that it is formed by combining an influenza receptor component and a solid carrier that specifically bind to the hemagglutinin (HA) protein of influenza.

According to the present invention, even if the virus contacts the human body, it is possible to drastically reduce the chance of infection by capturing and inactivating the virus using an influenza binding derivative and a carrier that bind to the surface of the virus.

1 is a conceptual diagram showing the application of the spray solution formulation for capturing influenza of the present invention.
2 is a diagram showing a synthesis example of a sialyllactose derivative according to an embodiment of the present invention.
3 is a diagram showing a synthesis example of a sialyllactose derivative according to another embodiment of the present invention.
Figure 4 is a view explaining examples of carriers used in the spray solution formulation for capturing influenza of the present invention.
5 is a view explaining the application of a spray solution formulation for influenza capture according to an embodiment of the present invention.
Figure 6 is a view explaining the application of a spray solution formulation for influenza capture according to another embodiment of the present invention.
7 is a graph showing the concentration of recombinant HA-his protein bound to a sialyllactose derivative according to the present invention.

The present invention, in one aspect,

A derivative for binding influenza and the remaining amount of additives;

The derivative for binding influenza provides a spray solution formulation for capturing influenza, characterized in that it is formed by combining an influenza receptor component and a solid carrier that specifically binds to the hemagglutinin (HA) protein of influenza.

In a further aspect of the present invention, the receptor component is sialyllactose α2,3-sialyl-lactose, α2,6-sialyl-lactose, sialyloligosaccharide, 3'-sialyllactose, 6'-sialyllactose, sialyllacto-N-tetraose lacto-N-tetraose), disialyl lacto-N-tetraose, and combinations thereof, or fucosyllactose.

In a further aspect, the present invention provides a spray solution formulation for capturing influenza, characterized in that the receptor component and the solid carrier are synthesized by a synthetic method by an esterification reaction and a ring-opening reaction.

The present invention, in another further aspect, provides a spray solution formulation for influenza capture, characterized in that the solid carrier is gelatin, casein, low molecular weight collagen or omega fatty acids.

In another further aspect of the present invention, the additives are solvents, solubilizers, diluents, emulsifiers, alcohols, preservatives, functional ingredients, antioxidants, natural preservatives, vitamins, natural flavors, moisturizers, humectants, surfactants, water-soluble polymers, stabilizers, inorganic salts, skin improvers, sunscreens, and cosmetic mists.

In another further aspect, the present invention provides a method for removing influenza using the spray solution formulation for capturing influenza.

Hereinafter, a spray solution formulation for capturing influenza according to the present invention and a method for removing influenza using the same will be described in detail with reference to the accompanying drawings.

The accompanying drawings are provided as examples to sufficiently convey the spirit of the present invention to those skilled in the art. Therefore, the present invention may be embodied in other forms without being limited to the drawings presented below, and the drawings presented below may be exaggerated to clarify the spirit of the present invention. At this time, unless there is another definition in the technical terms and scientific terms used, they have meanings commonly understood by those of ordinary skill in the art to which this invention belongs, and the gist of the present invention in the following description and accompanying drawings. Descriptions of known functions and configurations that may unnecessarily obscure will be omitted.

1 is a conceptual diagram showing the application of the spray solution formulation for capturing influenza of the present invention, FIG. 2 is a diagram showing a synthesis example of a sialyllactose derivative according to one embodiment of the present invention, FIG. 3 is a diagram showing a synthesis example of a sialyllactose derivative according to another embodiment of the present invention, FIG. 4 is a diagram explaining an example of a carrier used in the spray solution formulation for capturing influenza of the present invention, and FIG. FIG. 6 is a diagram illustrating application of a spray solution formulation for influenza capture according to another embodiment of the present invention, and FIG. 7 is a graph showing the concentration of recombinant HA-his protein bound to a sialyllactose derivative according to the present invention.

As used herein, the term "influenza receptor component" or "influenza binding derivative" refers to a compound or a derivative thereof that specifically binds to the Hemagglutinin (HA) protein of influenza and has a carrier-binding portion, and in specific embodiments, includes sialyllactose or fucosyllactose as described later.

As shown in FIGS. 1 to 7, a feature of the configuration of the present invention is that a lactose compound that specifically binds to influenza and a lactose derivative to which a solid carrier immobilized on the surface of the lactose compound binds to the lactose derivative, so that viruses in the air are preferentially bound to the derivative, and the derivative is recognized as a host by a mechanism unique to the virus, causing a change in the surface of the virus and inactivating the virus on or around the human body, thereby preventing viral infection.

The spray solution formulation 100 for capturing influenza according to the present invention includes an influenza receptor component that specifically binds to the hemagglutinin (HA) protein of influenza and a solid carrier immobilized on its surface (201-204) binding derivatives (401, 402); And the remaining amount of additives; characterized in that it comprises a.

The virus may be a pathogen capable of transmitting through the air. Furthermore, the highly pathogenic virus may be a pathogen that infects animals as well as humans, and as a specific and non-limiting example, the highly pathogenic virus may be avian flu, foot-and-mouth disease or new influenza virus, but the present invention is not limited thereto.

Influenza Receptor Ingredients

It includes a compound that specifically binds to the hemagglutinin (HA) protein of influenza and can bind to a carrier.

Receptor compounds capable of binding on the solid carrier include sialyllactose, α2,3-sialyl-lactose, α2,6-sialyl-lactose, sialyloligosaccharide, 3'-sialyllactose, 6'-sialyllactose, sialyllactose-N-tetraose It may be preferably fucosyllactose or a compound selected from the group consisting of o-N-tetraose), disialyl lacto-N-tetraose, and combinations thereof.

A “sialyllactose” may include a molecule comprising a lactose moiety (β-D-galactopyranosyl-(1→4)-D-glucose) bound to a sialic acid moiety. The sialic acid can be coupled to lactose by any possible position in the sialic acid and coupled to any possible position in the lactose molecule. In a more preferred form, the sialic acid is bonded to the lactose through the hydroxy group at the 2 position of the sialic acid (the numbering of the sialic acid structure starts at the carbon bearing the hydroxy group and continues around the chain).

In another preferred embodiment, the sialic acid is bonded to the lactose via a hydroxyl group at the 3rd or 6th position in the lactose molecule. In a more preferred embodiment, the "sialyllactose" is α2,3-sialyl-lactose or α2,6-sialyl-lactose. Sialyllactose may be of eukaryotic or prokaryotic origin.

Preferably the sialyllactose is of eukaryotic origin. The eukaryotic or prokaryotic cells may be pathogenic or non-pathogenic. For example, NeuAca2-3Galb1-3GalNAc, NeuAca2-3Galb1-3(4)GlcNAc, or NeuAca2-6Galb1-4GlcNAc) can be identified by solid phase analysis based on the ability of immobilized sialoadhycins to bind to human erythrocytes that have been derivatized to include sialic acid [Vinson M, et al, J Biol Chem 19 96; 271:9267-9272]

More preferred examples of the sialyllactose include, but are not limited to, sialyloligosaccharide, 3'-sialyllactose, 6'-sialyllactose, sialyllacto-N-tetraose, and disialyllacto-N-tetraose. -tetraose) and combinations thereof.

On the other hand, 2-fucosyllactose has been reported to be a major HMO (human milk oligosaccharides) involved in various biological activities, and is known to be the most abundant among oligosaccharides contained in breast milk. It has attracted attention as a material for infant formula and health functional food for the elderly and as a material for pharmaceuticals.

As a production method of fucosyllactose, there are a method of extracting it directly from breast milk and a method of synthesizing it by chemical or enzymatic methods.

There are two pathways for biosynthetic fucosyllactose, a salvage biosynthetic pathway and a de novo biosynthetic pathway.

In the Salvage synthesis method, while L-fucose consumes ATP inside the cell, it is phosphorylated by L-fucose kinase (fkp) to become Lfucose-1-phosphate, and it is combined with guanosine triphosphate (GTP) by L-fucose-1-phosphate guanylyl-transferase to form GDP-fucose, and then fucose is produced from lactose through fucose transferase.

In the de novo synthesis method, fructose-6-phosphate, an intermediate in glycolysis, is metabolized into mannose-1-phosphate by mannose-6-phosphate isomerase (ManA) and phosphomannomutase (ManB), and combined with GTP by mannose-1-phosphate guanyltransferase (ManC) to form GDP-D-mannose. Then, GDP-D-mannose 4,6-dehydratase (Gmd) removes water molecules from GDP-D-mannose, and GDP-L-fucose synthase (WcaG) promotes the reduction of the keto group at the C4 position of GDP-4-keto-6-deoxymannose. produce

Bioengineering production methods using microorganisms are in the spotlight because they are suitable for industrial mass production compared to other systems such as chemical synthesis or enzymatic synthesis in that they can produce 2-fucosyllactose in large quantities from inexpensive substrates through simple processes.

Solid phase carrier (201 ~ 204)

A variety of materials (carriers) can be used that allow the receptor component to adhere well to a surface.

Materials suitable as the solid carrier include, but are not limited to, cross-linked synthetic polymers including, but not limited to, styrene or styrene derivatives, divinylbenzene, acrylamides, acrylate esters, methacrylate esters, vinyl esters, vinyl amides; natural polymers such as agarose, alginates, carrageenan, gelatin, and cellulose; or derivatized natural polymers such as cellulose acetate or nitrocellulose and silica, glass, especially glass fibers;

The natural polymers are known to spontaneously form a physically cross-linked network upon cooling or addition of divalent metal ions, and chemical cross-linkers may be added as needed.

The carrier may take the form of strips, spheres, rods, tubes and microassays or microtiter plates. Sheet-like structures such as paper strips, small plates and membranes are likewise suitable. The surface of the support may or may not be permeable to an aqueous solution.

Thus, in summary, the carrier material can in principle be any material that allows covalent coupling to the sialyllactose molecule of the present invention [References: Lee M, Shin I, et al 2005 Facile preparation of carbohydrate microarrays by site-specific, covalent immobilization of unmodified carbohydrates on hydrazide-coated glass slides Org Lett 7: 4269-4272; Fukui S, Feizi T, Galustian C, Lawson AM, Chai WG, et al 2002 Oligosaccharide microarrays for highthroughput detection and specificity assignments of carbohydrateprotein interactions Nat Biotechnol 20: 1011-1017)]

The solid carrier may be more preferably gelatin (201), casein (202), low molecular weight collagen (203), or omega-3, -6 fatty acids (204) as shown in FIG.

The lactose derivative may be preferably included in an amount of 5 to 95 parts by weight based on the weight of the spray solution formulation for capturing influenza of the present invention.

Bonding of sialyllactose molecules

By using a spray, the following carriers that can adhere well to surfaces such as human skin or disposable masks can be combined through chemical reactions.

A method of binding the lactose compound 301 to the solid carriers 201 to 204 may be performed by a conventional esterification reaction and a ring opening reaction.

As shown in FIG. 2, it is preferable to prepare sialyllactose derivatives (401, 402) by carrying out a compounding reaction (S201, S202) with gelatin (201), casein (202), low-molecular-weight collagen (203), or omega-3 fatty acid (204) harmless to the human body using sialyllactose molecules (301) as carriers.

additive

The additive may include, but is not limited to, at least one selected from solvents, solubilizers, diluents, emulsifiers, alcohols, preservatives, functional ingredients, antioxidants, natural preservatives, vitamins, natural flavors, moisturizers, humectants, surfactants, water-soluble polymers, stabilizers, inorganic salts, skin improvers, sunscreens, and cosmetic mists commonly used in the art.

Examples of the solvent, solubilizing agent, diluent or emulsifying agent include water, ethanol, isopropanol, propylene glycol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, lactose, 1,3-butyl glycol oil, glycerol aliphatic esters, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, polyethylene glycol or fatty acid esters of sorbitan, Chlorofluorohydrocarbons, propane/butane or dimethyl ethers, aliphatic alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters, aloe vera source Liquid, uric acid, hyaluronic acid, complex vitamins, and the like may be used.

The multivitamin may include vitamin B, vitamin C, vitamin D2 and vitamin E.

The vitamin B may include vitamin B5 and vitamin B6. The multivitamin may further include vitamin A.

The preservative is citric acid, propionic acid, propionate, salicylic acid, salicylic acid, sorbic acid, sorbate, zinc pyrithione, hexetidine, polyaminopropyl biguanide, methenamine, dimethyl oxazolidine azolidine), diazolidinyl urea, and glutaral.

As functional ingredients, at least one selected from olive oil, olive liquid, grape seed oil, chamomile undiluted solution, chamomile oil, broccoli undiluted solution, loofah undiluted solution, lavender oil, Yonggyu undiluted solution, zinc oxide, peptide nanosomes, hydroquinone, and EGF (Epidermal growth factor) may be further included.

The antioxidant may include at least one selected from gamma-oryzanol, rosemanol, epigallocatechingallate, epigallocatechin, and noni extract.

The natural preservative may include at least one selected from limonene, phenoxyethanol, yonggyu extract, coriander tree ethanol extract, fermented cinnamon hot water extract, perilla leaf hot water extract, and artemisiae annuae herba hot water extract.

Natural fragrances include various plant fragrances including pine needle oil, lavender oil, or pine oil.

In addition, 1,3-butylene glycol, glycerin, trehalose, sodium PCA, etc. may be mentioned as a humectant component.

The ingredients listed above can be selected according to the purpose of use within a range that does not impair the effects of the present invention.

The solution may be preferably included in an amount of 5 to 95 parts by weight based on the weight of the spray solution formulation for capturing influenza of the present invention.

In the method for removing influenza using a lactose derivative according to the present invention, as shown in FIGS. 5 and 6, the spray solution preparation 100 for capturing influenza is sprayed on the surface of the mask 501 or around the nose 601 or sprayed on the hand to specifically bind with influenza trying to penetrate the respiratory tract to capture and inactivate influenza, thereby preventing viral infection in a harmless manner to the human body.

The spray solution preparation for capturing influenza according to the present invention can be used daily or for an unspecified period of time, and preferably, the amount, frequency and duration of use can be adjusted according to the user's age, skin condition or skin type, and the concentration of the sialyllactose.

<Example>

Hereinafter, the present invention will be more specifically described by the following representative examples, but the present invention is not limited in any way by these examples.

Example 1: Synthesis of Sialyllactose Derivative (401)

The following carriers (carriers) that can adhere well to surfaces such as human skin or disposable masks using sprays were combined through chemical reactions.

Gelatin (201), casein (202), and low-molecular-weight collagen (203), which are harmless to the human body, were selected as carriers, and a chemical bonding reaction was performed as follows. A sialyllactose derivative (401) was synthesized by dissolving 0.5 mM gelatin in acetic acid, adding 0.1 mM sialyllactose (acetic acid) [6'-sialyllactose sodium salt: Tokyo chemical industry, S0886] and incubating at 60°C for 90 minutes.

Example 2: Sialyllactose derivatives containing fatty acids (402) synthesis

The following carriers that can adhere well to surfaces such as human skin or disposable masks using sprays are combined through chemical reactions.

Gelatin (201), casein (202), or self-molecular collagen (203) and omega-3 fatty acid (204), which are non-toxic to the human body, were selected as carriers, and a chemical bonding reaction was performed as follows. In addition, derivatives containing omega 3 and 6 fatty acids were also synthesized.

For the detailed experimental method, first, a chemical reaction was carried out by esterification with carboxylic acid (-COOH) of omega-3 (DHA) and hydroxyl group (-OH) of gelatin.

0.2mM omega 3 was dissolved in 10mL DMSO, which dissolves well, and 3 equivalents of DCC were added and combined. Organic matter (ethyl acetate) was put in a separatory funnel, washed several times with water, and dried. The synthesized gelatin-omega was dissolved in acetic acid, and 0.1 mM sialyllactose (acetic acid) [6'-sialyllactose sodium salt: tokyo chemical industry, S0886] was added thereto and incubated at 60 ° C for 90 minutes to synthesize a fatty acid-containing sialyllactose derivative (402).

Example 3: Test for confirming the presence or absence of sialyllactose on the surface

The solution synthesized in Examples 1 and 2 was diluted to 10%, put in a 50mL spray container, sprayed three times on 8 wells of a well plate used for immunoenzyme reaction, and after 10 minutes, the recombinant HA-his protein (HA-his protein of H1N1, A/california/07/2009 virus: Sino Biological, 11085-V08H-100 at 0ng/mL, 1ng/mL, 5ng/mL, Divided into 10ng/mL, 50ng/mL, 100ng/ml, 500ng/mL, and 1000ng/mL, 50 μl each was added. After 30 minutes, washed 5 times with 0.005 tween 20 (1XPBS). After that, HRP conjugated anti-his tag antibody (abcam, Cambridge, UK) diluted 1:5000 was added to the 8 wells at 100 Dispensed by μl, and aged at room temperature for 30 minutes.Then, the plate was washed 5 times with 0.005 tween 20 (1 X PBS) 5 times with a washing solution, and then 50 μl of TMB (tetramethylbenzidine) was dispensed into 8 wells, and then color developed at room temperature.After 5 minutes, it was confirmed with an optical reader, and the results are shown in FIG.

7 is a graph showing the concentration of recombinant HA-his protein bound to a sialyllactose derivative according to the present invention. As confirmed from the results of FIG. 7, the quantitative results of Examples 1 and 2 were confirmed for each recombinant HA-his protein concentration.

Example 4: Preparation of a spray solution for capturing influenza

A spray solution for influenza capture was prepared by mixing the sialyllactose derivatives of Examples 1 and 2 with the additives shown in Table 1 below (unit g).

Ingredients/Amount Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Inductor (401) 5 2 50 - One Inductor (402) - 3 - 95 - propylene glycol 10 5 5 - 5 hyaluronic acid 10 5 10 - - vitamin C 10 5 - - 5 glycerin 10 5 5 - - Purified water 10 50 10 5 70 limonene 10 5 - - - citric acid 10 5 5 - 5 olive oil 10 5 10 - 5 rosmanol 10 5 5 - 4 lavender oil 5 5 - - - Sum 100 100 100 100 100

Test Example 1: Clinical application of spray products

For the spray products according to Example 3 and Comparative Example 1, a sensory test was performed by selecting 50 sensory testers. The degree of improvement in the items of frequency of infectious diseases, skin trouble, moisturizing effect, and fragrance was evaluated using a 7-point scale (7 points: very good, 6 points: good, 5 points: slightly good, 4 points: average, 3 points: slightly bad, 2 points: bad, 1 point: very bad). As sensory test items, a total of four sensory items such as the frequency of infectious diseases, skin trouble, moisturizing effect, and overall preference were evaluated, and the results were verified by Duncan's multiple range test at the 5% level using ANOVA. Significant differences between samples were verified. The results are shown in Table 2 (average value ± standard deviation) below.

item Example 3 Comparative Example 1 frequency of infectious diseases 6.12±0.21 2.61±0.35 Skin trouble 6.64±0.35 2.25±0.33 moisturizing effect 6.65±0.33 2.43±0.30 orientation characteristics 6.63±0.38 2.76±0.31 overall sign 6.62±0.36 2.34±0.32

As a result, the product of Example 3 showed very satisfactory results in all items. From the results of Table 2, it was confirmed that the products of the examples of the present invention are generally superior to those of the comparative products. From the above results, the preparation according to the present invention can be used in the prevention-oriented healthcare industry that can be used continuously without side effects for the purpose of preventing influenza-related diseases.

In the above, the embodiments of the present invention have been described with reference to the accompanying drawings, but those skilled in the art to which the present invention pertains may be implemented in other specific forms without changing the technical spirit or essential features of the present invention. It will be understood that it can be practiced. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive.

100: spray formulation
201: gelatin
301: sialyllactose
401: sialyllactose derivative

Claims (1)

5 to 95 parts by weight of a derivative for binding influenza and 5 to 95 parts by weight of the remaining amount of additives;
The influenza binding derivative is made by combining an influenza receptor component and a solid carrier that specifically bind to the hemagglutinin (HA) protein of influenza,
The receptor component is sialyllactose α2,3-sialyl-lactose, α2,6-sialyl-lactose, sialyloligosaccharide, 3'-sialyllactose, 6'-sialyllactose, sialyllacto-N-tetraose, A compound or fucosyllactose selected from the group consisting of disialyl lacto-N-tetraose and combinations thereof,
The solid carrier is gelatin, casein, low molecular weight collagen, or omega fatty acids,
The receptor component and the solid carrier are bonded by an esterification reaction and a ring-opening reaction,
The additives include at least one selected from solvents, solubilizers, diluents, emulsifiers, alcohols, preservatives, functional ingredients, antioxidants, natural preservatives, vitamins, natural flavors, moisturizers, humectants, surfactants, water-soluble polymers, stabilizers, inorganic salts, skin improvers, sunscreens, and cosmetic mists. A spray solution formulation for capturing influenza, characterized in that it comprises at least one selected from loofah stock solution, lavender oil, Yonggyu stock solution, zinc oxide, peptide nanosomes, hydroquinone, and EGF (Epidermal growth factor).